| Immunotherapy: a challenge of breast cancer treatment M García-Aranda, M Redondo Cancers 11 (12), 1822, 2019 | 151 | 2019 |
| Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies E Pérez-Ruiz, I Melero, J Kopecka, AB Sarmento-Ribeiro, ... Drug Resistance Updates 53, 100718, 2020 | 127 | 2020 |
| Bcl-2 inhibition to overcome resistance to chemo-and immunotherapy M García-Aranda, E Pérez-Ruiz, M Redondo International journal of molecular sciences 19 (12), 3950, 2018 | 126 | 2018 |
| Protein kinase targets in breast cancer M García-Aranda, M Redondo International journal of molecular sciences 18 (12), 2543, 2017 | 74 | 2017 |
| Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy … M Redondo, T Téllez, MJ Roldan, A Serrano, M García-Aranda, ... Breast Cancer Research 9, 1-8, 2007 | 60 | 2007 |
| Targeting receptor kinases in colorectal cancer M García-Aranda, M Redondo Cancers 11 (4), 433, 2019 | 58 | 2019 |
| Targeting protein kinases to enhance the response to anti-PD-1/PD-L1 immunotherapy M García-Aranda, M Redondo International journal of molecular sciences 20 (9), 2296, 2019 | 43 | 2019 |
| Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer. RM García-Aranda M, Téllez T, Muñoz M Anticancer Drugs., 2017 | 37* | 2017 |
| Regulation of clusterin gene expression M Garcia-Aranda, A Serrano, M Redondo Current Protein and Peptide Science 19 (6), 612-622, 2018 | 27 | 2018 |
| The role of clusterin in carcinogenesis and its potential utility as therapeutic target T Tellez, M Garcia-Aranda, M Redondo Current Medicinal Chemistry 23 (38), 4297-4308, 2016 | 25 | 2016 |
| Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction J Oliver, M Garcia-Aranda, P Chaves, E Alba, M Cobo-Dols, JL Onieva, ... Seminars in cancer biology 83, 584-595, 2022 | 20 | 2022 |
| Neurokinin-1 receptor (NK-1R) antagonists as a new strategy to overcome cancer resistance M García-Aranda, T Téllez, L McKenna, M Redondo Cancers 14 (9), 2255, 2022 | 13 | 2022 |
| Free thyroxine determination in the emergency department is a predictor of acute pancreatitis evolution G Callejón, E Redondo, M Garcia-Aranda, JA Castilla-Alcalá, ... Pancreas 47 (10), 1322-1327, 2018 | 4 | 2018 |
| Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells M Redondo, M García-Aranda, MJ Roldan, G Callejón, A Serrano, ... Anti-Cancer Drugs 26 (1), 85-89, 2015 | 4 | 2015 |
| Clusterin expression in colorectal carcinomas T Téllez, D Martin-García, M Redondo, M García-Aranda International Journal of Molecular Sciences 24 (19), 14641, 2023 | 2 | 2023 |
| Impact of detection mode in a large cohort of women taking part in a breast screening program M García, M Redondo, I Zarcos, J Louro, F Rivas-Ruiz, T Téllez, D Pérez, ... European Journal of Breast Health 18 (2), 182, 2022 | 2 | 2022 |
| Effect of physical rehabilitation in patients with hereditary spinocerebellar ataxia. A systematic review A Marchal-Muñoz, M García-Aranda, M Marchal-Muñoz, ... Rehabilitacion 54 (3), 200-210, 2020 | 2 | 2020 |
| First hospital contact via the Emergency Department is an independent predictor of overall survival and disease-free survival in patients with colorectal cancer RBM Téllez T, García-Aranda M, Zarcos-Pedrinaci I, Rivas-Ruiz F, Pérez Ruiz ... Rev Esp Enferm Dig, 2019 | 2* | 2019 |
| Clinical–pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of patients with colorectal tumours Tumor Biology, 2019 | 2* | 2019 |
| Analysis of the association between adverse events and outcome in patients receiving a programmed death protein-1 or programmed death ligand-1 antibody M García-Aranda, M Redondo Chinese Clinical Oncology 9 (4), 57-57, 2020 | 1 | 2020 |
Teresa TellezProfesor de Bioquímica, Universidad de MálagaVerified email at uma.es
